LSTA earnings analysis
What we found in LSTA's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lisata Therapeutics reported a net loss of $4.49 million for Q1 2026, a slight improvement from a loss of $4.72 million in Q1 2025. Operating expenses decreased by 15.5% to $4.94 million, driven by reduced R&D costs. The company continues to seek additional funding amid significant liquidity challenges, with $13.1 million in cash on hand as of March 31, 2026.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improved Net Loss
- Net loss reduced to $4.49 million in Q1 2026 from $4.72 million a year ago.
- Decrease in Operating Expenses
- Operating expenses declined by 15.5% to $4.94 million, down from $5.85 million.
- Cash Position
- Cash and cash equivalents available were approximately $13.1 million as of March 31, 2026.
- Research Expenses Cut by 53.7%
- R&D expenses fell to $1.2 million from $2.6 million for the same period last year.
- Legal and Consulting Fees Increase
- General and administrative expenses rose by 15.2% to $3.7 million, reflecting increased legal costs.
- Cash Used in Operations Improves
- Cash used in operating activities decreased, totaling $3.1 million, down from $5.4 million in the previous year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Merger Uncertainty
- The proposed acquisition by Kuva is pending, with no guarantee of closure by the May 29, 2026 deadline.
- Ongoing Liquidity Challenges
- Lisata faces substantial doubt about continuing operations, having to secure additional funding.
- Potential Shareholder Distrust
- Failure to complete the merger could lead to a decline in investor confidence and stock price.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.62
What they said about what is next.
No explicit guidance provided in the filing; Management anticipates potential capital needs.
The filing reads about the same as the one before it.
What came before.
- 10-K · April 28, 2026
- Lisata reports modest operational signs of stabilization (revenue of $100,000 in 2025Q4 and diluted EPS improving to -$0.33) but remains a loss-making, cash‑burning clinical-stage company (free cash flow -$3.0M in…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LSTA makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever